Vivanza Biosciences Limited (BOM:530057)
1.860
-0.060 (-3.12%)
At close: Jun 17, 2026
Vivanza Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,159 | 74.23 | 278.35 | 178.07 | 104 |
Other Revenue | 1.12 | 0.48 | 0.54 | 3.47 | 7.99 |
| 1,160 | 74.72 | 278.89 | 181.54 | 111.99 | |
Revenue Growth (YoY) | 1452.84% | -73.21% | 53.62% | 62.10% | 12.67% |
Cost of Revenue | 1,144 | 68.21 | 259.51 | 165.06 | 96.54 |
Gross Profit | 15.96 | 6.51 | 19.39 | 16.48 | 15.46 |
Selling, General & Admin | 4.92 | 5.98 | 4.51 | 3.51 | 3.24 |
Other Operating Expenses | 2.59 | 3.44 | 3.67 | 1.6 | 3.65 |
Operating Expenses | 7.73 | 9.56 | 8.3 | 5.13 | 6.96 |
Operating Income | 8.23 | -3.05 | 11.08 | 11.35 | 8.5 |
Interest Expense | -2.79 | -3.51 | -4.13 | -4.19 | -4.06 |
Currency Exchange Gain (Loss) | - | -0.09 | - | - | -1.1 |
Other Non Operating Income (Expenses) | 0 | -0 | - | - | -0 |
EBT Excluding Unusual Items | 5.44 | -6.66 | 6.95 | 7.16 | 3.33 |
Pretax Income | 5.44 | -6.66 | 6.95 | 7.16 | 3.33 |
Income Tax Expense | 1.49 | 0.08 | 1.48 | 1.18 | 0 |
Net Income | 3.94 | -6.74 | 5.47 | 5.98 | 3.33 |
Net Income to Common | 3.94 | -6.74 | 5.47 | 5.98 | 3.33 |
Net Income Growth | - | - | -8.52% | 79.67% | 342.02% |
Shares Outstanding (Basic) | 39 | 40 | 39 | 40 | 40 |
Shares Outstanding (Diluted) | 39 | 40 | 39 | 40 | 40 |
Shares Change (YoY) | -1.40% | 2.32% | -2.27% | - | - |
EPS (Basic) | 0.10 | -0.17 | 0.14 | 0.15 | 0.08 |
EPS (Diluted) | 0.10 | -0.17 | 0.14 | 0.15 | 0.08 |
EPS Growth | - | - | -6.40% | 80.21% | 340.72% |
Free Cash Flow | -27.03 | -25.07 | 20.06 | -9.46 | 24.67 |
Free Cash Flow Per Share | -0.69 | -0.63 | 0.51 | -0.24 | 0.62 |
Gross Margin | 1.38% | 8.71% | 6.95% | 9.08% | 13.80% |
Operating Margin | 0.71% | -4.08% | 3.97% | 6.25% | 7.58% |
Profit Margin | 0.34% | -9.02% | 1.96% | 3.30% | 2.97% |
Free Cash Flow Margin | -2.33% | -33.55% | 7.19% | -5.21% | 22.03% |
EBITDA | 8.45 | -2.91 | 11.2 | 11.38 | 8.57 |
EBITDA Margin | 0.73% | -3.90% | 4.02% | 6.27% | 7.65% |
D&A For EBITDA | 0.22 | 0.14 | 0.12 | 0.03 | 0.07 |
EBIT | 8.23 | -3.05 | 11.08 | 11.35 | 8.5 |
EBIT Margin | 0.71% | -4.08% | 3.97% | 6.25% | 7.58% |
Effective Tax Rate | 27.47% | - | 21.27% | 16.48% | 0.12% |
Revenue as Reported | 1,160 | 74.85 | 278.89 | 182.82 | 112.29 |
Advertising Expenses | - | 0.05 | 0.04 | 0.08 | 0.03 |